Why are PPAR agonists a promising option for the management of NASH ?
Lipotoxicity in NASH
Prof Szabo, USA discusses the progresses of the quest of biomarkers in NASH
Learn more about the burden of the disease, Prof Sven Francque, Belgium
What are the current definitions ? Prof Abdelmalek, USA
An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA
